Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips

Omeros reported a Q1 2026 EPS miss of -$0.24 versus -$0.12 expected and revenue of $9.89 million versus $40.15 million expected, but the launch of YARTEMLEA showed strong early traction with $11.1 million gross sales and $9.9 million net revenue. Management said the drug was cash flow positive in its first quarter, with FDA approval, a permanent CMS J-code, and a recommended NTAP supporting reimbursement and adoption. Shares fell 2.57% on the release but recovered 1.27% after hours.

Analysis

The market is still treating this like an execution story, but the more important change is that OMER has crossed from binary-development to distributed commercialization. That shifts the earnings model from one-time launch noise to a compounding reimbursement flywheel: once a therapy is embedded in hospital pathways, incremental demand can rise faster than headline prescriptions because stocking, billing, and protocolization all reinforce each other. The near-term upside is not just volume; it is operating leverage from a fixed field force spreading across a niche but high-acuity network.

The cleanest second-order winner is NVO, because the upfront capital effectively underwrites OMER’s launch without forcing near-term dilution. For OMER, the key nuance is that apparent EPS volatility is mostly irrelevant until the stock stabilizes above note-conversion thresholds; the real sensitivity is cash burn versus launch acceleration over the next 2-3 quarters. If reimbursement frictions clear on schedule, the market may rerate the revenue multiple before the P&L turns positive, but if center adoption stalls after the initial wave, consensus is likely overestimating the slope of penetration.

AZN is the relative loser on the competitive side: even if its program advances, it now has to prove differentiated efficacy in a setting where physicians are being educated earlier and are already forming treatment habits. The larger issue is endpoint risk in competing studies; if trials focus on softer or later-stage endpoints, they may validate the need for earlier intervention while failing to capture it commercially. CMS is an indirect beneficiary only insofar as permanent coding and NTAP should reduce administrative drag; that tends to accelerate conversion from inpatient use to standard protocol status with a lag of 1-2 quarters.

The contrarian read is that the stock move may still be underdone, not because the quarter was strong, but because the launch math is being mis-modeled. Investors are anchoring to the EPS miss instead of the fact that reimbursement catalysts land over the next 60-120 days, which can matter more than current-quarter sales. The main tail risk is not demand, but a slower-than-expected expansion beyond the first 20-30 accounts; if that happens, the market will quickly reprice OMER back toward a single-asset launch risk multiple.

Key Decisions for Investors

• Long OMER for 3-6 months into J-code and NTAP catalysts; downside is limited if cash burn stays controlled, while upside is a rerating if account expansion continues past the first 30 centers.
• Pair trade: long OMER / short AZN for 1-2 quarters; thesis is that commercial adoption in a rare, high-acuity indication can outpace a competing trial narrative that still carries endpoint and timing risk.
• Overweight NVO on any pullback as the capital partner with asymmetric optionality; the main risk is not economics but that OMER’s launch momentum fades before milestone realization becomes material.
• Use call spreads on OMER rather than stock if liquidity is a concern; the setup is best captured by upside convexity into reimbursement milestones, with defined risk if launch data disappoints.